Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. uri icon

Overview

abstract

  • This corrects the article DOI: 10.1038/ncomms15987.

publication date

  • March 13, 2018

Identity

PubMed Central ID

  • PMC5857674

Scopus Document Identifier

  • 85058610087

Digital Object Identifier (DOI)

  • 10.1038/ncomms16187

PubMed ID

  • 29532792

Additional Document Info

volume

  • 9